| Schedule of net product revenues by product |
The Company’s net revenues consisted of the following for the three and six months ended June 30, 2026 and 2025: | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Products: | | | | | | | | | Talicia | $ | 2,349,890 | | | $ | — | | | $ | 4,266,370 | | | $ | — | | | Sancuso | 1,816,737 | | | 3,119,112 | | | 4,745,372 | | | 4,079,920 | | | Vibativ | 1,738,887 | | | 2,701,854 | | | 3,857,183 | | | 6,238,609 | | | Kristalose | 1,061,442 | | | 2,754,299 | | | 2,042,926 | | | 5,375,405 | | | Caldolor | 1,474,288 | | | 1,588,293 | | | 2,439,852 | | | 2,895,733 | | | Acetadote | 136,661 | | | 193,544 | | | 188,643 | | | 345,195 | | | Vaprisol | — | | | (14,621) | | | 518 | | | (15,221) | | | Omeclamox-Pak | — | | | (752) | | | — | | | (6,139) | | | RediTrex | 1,802 | | | 3,244 | | | 1,311 | | | 2,897 | | | Other revenue | 221,534 | | | 492,390 | | | 390,384 | | | 3,634,019 | | | Total revenue | 8,801,241 | | | $ | 10,837,363 | | | 17,932,559 | | | 22,550,418 | | | Less discontinued operations | (8,634,783) | | | $ | (10,456,566) | | | $ | (17,602,251) | | | $ | (22,002,993) | | | Revenue from continuing operations | $ | 166,458 | | | $ | 380,797 | | | $ | 330,308 | | | $ | 547,425 | | | | | | | | | |
|